Search results for "hepatology"

showing 10 items of 2737 documents

What could have caused this weight loss?

2016

International audience; Achalasia is rare and often diagnosed late.It is characterized by functional gastro-oesophageal sphincter obstruction.Aspiration pneumonia may complicate the achalasia.Intrasphincteric botulinum toxin injection is one of the main treatments for achalasia.

medicine.medical_specialtyBotulinum ToxinsAchalasiaBotulinum toxin injection[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyAspiration pneumoniaPneumonia AspirationGastroenterologydigestive systemEndoscopy Gastrointestinal03 medical and health sciences0302 clinical medicineWeight lossInternal medicineWeight LossInternal Medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicineComputingMilieux_MISCELLANEOUSAged 80 and overmedicine.diagnostic_test[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologybusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologydigestive oral and skin physiologyAchalasia[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologydigestive system diseases3. Good healthEndoscopyEsophageal AchalasiaPneumoniamedicine.anatomical_structureSphincter030211 gastroenterology & hepatologyFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusiness
researchProduct

Stretching the boundaries for liver transplant in the 21st century.

2018

Given the high waiting list mortality, there is a clear need to identify strategies to increase the number of livers for transplantation. Some strategies require policy changes, whereas others depend on a better understanding of available opportunities. We divided the strategies to increase the number of livers for transplantation into two categories-those aiming to increase the use of organs considered to be of suboptimal quality, and those aiming to increase the use of organs considered to be of suboptimal size. Enough evidence suggests that, if considered in the context of other donor and recipient variables, grafts from elderly donors are a safe option. The severity of steatosis, and no…

medicine.medical_specialtyBrain DeathWaiting ListsContext (language use)030230 surgery03 medical and health sciencesLiver disease0302 clinical medicinemedicineLiving DonorsHumansIntensive care medicineCause of deathMachine perfusionHepatologybusiness.industryFatty liverGastroenterologyAge FactorsHepatitis Cmedicine.diseaseHepatitis CTissue DonorsLiver TransplantationTransplantationFatty LiverDonationKidney Failure Chronic030211 gastroenterology & hepatologybusinessThe lancet. Gastroenterologyhepatology
researchProduct

Appendectomy during the COVID-19 pandemic in Italy: a multicenter ambispective cohort study by the Italian Society of Endoscopic Surgery and new tech…

2021

AbstractMajor surgical societies advised using non-operative management of appendicitis and suggested against laparoscopy during the COVID-19 pandemic. The hypothesis is that a significant reduction in the number of emergent appendectomies was observed during the pandemic, restricted to complex cases. The study aimed to analyse emergent surgical appendectomies during pandemic on a national basis and compare it to the same period of the previous year. This is a multicentre, retrospective, observational study investigating the outcomes of patients undergoing emergent appendectomy in March–April 2019 vs March–April 2020. The primary outcome was the number of appendectomies performed, classifie…

medicine.medical_specialtyCOVID-19 PandemicCoronavirus disease 2019 (COVID-19)Endoscopic surgeryNOAppendectomy; Appendicitis; COVID-19 Pandemic; Machine learningCohort Studies03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRetrospective StudiePandemicMachine learningmedicineHumansAppendectomyAppendicitiLaparoscopyPandemicsRetrospective Studiesmedicine.diagnostic_testPandemicbusiness.industryCOVID-19 Pandemic Appendicitis Appendicectomy Machine learningSARS-CoV-2COVID-19Length of Staymedicine.diseaseAppendicitisAppendicitisSettore MED/18SurgeryItaly030220 oncology & carcinogenesisAppendectomy; appendicitis; COVID-19 pandemic; machine learning; appendectomy; cohort studies; humans; Italy; length of stay; pandemics; postoperative complications; retrospective studies; SARS-CoV-2; appendicitis; COVID-19; laparoscopy030211 gastroenterology & hepatologySurgeryObservational studyOriginal ArticleLaparoscopyPostoperative ComplicationAppendicectomyCohort StudiebusinessComplicationCohort studyHuman
researchProduct

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives

2022

La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la incidencia como la gravedad de la enfermedad. La enfermedad inflamatoria intestinal (EII) representa una condición especial asociada con una respuesta descontrolada del sistema inmunológico a agentes externos. Los tratamientos para la EII se han asociado con un mayor riesgo de infecciones bacterianas y virales. Esto ha planteado la cuestión de una posible mayor incidencia y gravedad de la infección por COVID-19 en pacientes con EII. A lo largo de este a…

medicine.medical_specialtyCOVID-19 VaccinesIBD-treatmentCOVID-19 VaccinePopulationDiseaseIncidencia por COVID-19COVID-19 graveInflammatory bowel diseaseSulfasalazineInternal medicinetratamiento de la EIIPandemicmedicineHumansEnfermedad Inflamatoria Intestina (EII)Inflammatory Bowel Disease (IBD)educationSevere COVID-19Pandemicseducation.field_of_studyTofacitinibHepatologybusiness.industryVacuna COVID-19Incidence (epidemiology)GastroenterologyRevisadoCOVID-19General Medicinemedicine.diseaseInflammatory Bowel DiseasesVaccinationCOVID-19 incidenceTumor Necrosis Factor Inhibitorsbusinessmedicine.drugGastroenterología y Hepatología (English Edition)
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

2021

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with va…

medicine.medical_specialtyCOVID19Health Toxicology and Mutagenesismedicine.medical_treatmentPopulation030232 urology & nephrologymedicine.disease_cause03 medical and health sciences0302 clinical medicineRenal DialysisSeroepidemiologic StudiesPandemicHepatitis VirusesmedicineSeroprevalenceHumanshepatitisIntensive care medicineeducationCoronavirusHepatitiseducation.field_of_studybusiness.industryTransmission (medicine)SARS-CoV-2RPublic Health Environmental and Occupational Healthvirus diseasesCOVID-19medicine.diseaseVaccinationEditorialMedicinedialysis030211 gastroenterology & hepatologyHemodialysisbusinesschronic kidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992.

1994

medicine.medical_specialtyCanadaMEDLINEIndiaEsophageal and Gastric VaricesJapanSurveys and QuestionnairesGastroscopyHypertension PortalmedicineHumansMulticenter Studies as TopicHepatologymedicine.diagnostic_testVascular diseasebusiness.industryGeneral surgeryConsensus conferencemedicine.diseaseUnited StatesEndoscopySurgeryEuropeItalyGastric MucosaPortal hypertensionbusinessJournal of hepatology
researchProduct

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

2021

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load. METHODS Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre-treatment serum HBV DNA and HCV RNA were quantified using Roche CO…

medicine.medical_specialtyCarcinoma Hepatocellular610 Medizin610 Medicine & healthChronic liver diseaseAntibodies Monoclonal HumanizedGastroenterologyRamucirumab03 medical and health sciencesLiver disease0302 clinical medicine610 Medical sciencesInternal medicineMedicineHumans030304 developmental biology0303 health sciencesHepatologybusiness.industryLiver NeoplasmsHepatitis CHepatitis Bmedicine.diseasedigestive system diseases3. Good healthClinical Trials Phase III as Topic030220 oncology & carcinogenesisHepatocellular carcinomaLiver functionbusinessViral load
researchProduct

Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.

2019

BACKGROUND AND AIMS Deciding when to repeat and when to stop transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) can be difficult even for experienced investigators. Our aim was to develop a survival prediction model for such patients undergoing TACE using novel machine learning algorithms and to compare it to conventional prediction scores, ART, ABCR and SNACOR. METHODS For this retrospective analysis, 282 patients who underwent TACE for HCC at our tertiary referral centre between January 2005 and December 2017 were included in the final analysis. We built an artificial neural network (ANN) including all parameters used by the aforementioned risk scores a…

medicine.medical_specialtyCarcinoma Hepatocellular610 MedizinPilot Projects03 medical and health sciences0302 clinical medicine610 Medical sciencesmedicineHumansIn patientInternal validationChemoembolization TherapeuticRetrospective StudiesHepatologyArtificial neural networkbusiness.industryLiver NeoplasmsPatient survivalClinical routinemedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyRadiologyNeural Networks ComputerbusinessArea under the roc curvePredictive modellingLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

2021

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk fac…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineantiviral therapymedicineHumansPropensity Scoreantiviral therapy; hepatocellular carcinoma; meta-analysisbusiness.industryLiver NeoplasmsGastroenterologyAntiviral therapyPatient datahepatocellular carcinomamedicine.disease3. Good healthmeta-analysis030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinomaRelative riskCohort030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeoplasm Recurrence LocalbusinessDirect acting
researchProduct